CoChat
Sign Up
Cited by 383Diabetes and associated disordersDiabetes Management and ResearchT-cell and B-cell Immunology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

Näntö-Salonen, Kirsti, Kupila, Antti, Simell, Satu, Siljander, Heli, Salonsaari, Tiina, Hekkala, Anne, Korhonen, Sari, Erkkola, Risto, Sipilä, Jukka I, Haavisto, Lotta, Siltala, Marja, Tuominen, Juhani, Hakalax, Jari, Hyöty, Heikki, Ilonen, Jorma, Veijola, Riitta, Simell, Tuula, Knip, Mikael, Simell, Olli·2008·The Lancet
DOI 10.1016/s0140-6736(08)61309-4
Open this paper in CoChat — free account

Abstract

Background In mouse models of diabetes, prophylactic administration of insulin reduced incidence of the disease. We investigated whether administration of nasal insulin decreased the incidence of type 1 diabetes, in children with HLA genotypes and autoantibodies increasing the risk of the disease. Methods At three university hospitals in Turku, Oulu, and Tampere (Finland), we analysed cord blood samples of 116 720 consecutively born infants, and 3430 of their siblings, for the HLA-DQB1 susceptibility alleles for type 1 diabetes. 17 397 infants and 1613 siblings had increased genetic risk, of whom 11 225 and 1574, respectively, consented to screening of diabetes-associated autoantibodies at every 3-12 months. In a double-blind trial, we randomly assigned 224 infants and 40 siblings positive for two or more autoantibodies, in consecutive samples, to receive short-acting human insulin (1 unit/kg; n=115 and n=22) or placebo (n=109 and n=18) once a day intranasally. We used a restricted randomisation, stratified by site, with permuted blocks of size two. Primary endpoint was diagnosis of diabetes. Analysis was by intention to treat. The study was terminated early because insulin had no beneficial effect. This study is registered with ClinicalTrials.gov, number NCT00223613. Findings Median duration of the intervention was 1.8 years (range 0-9.7). Diabetes was diagnosed in 49 index children randomised to receive insulin, and in 47 randomised to placebo (hazard ratio [HR] 1.14; 95% C…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61309-4

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 383

Related

See all

Metadata

Authors
Näntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., Siltala, M., Tuominen, J., Hakalax, J., Hyöty, H., Ilonen, J., Veijola, R., Simell, T., Knip, M., & Simell, O.
Affiliations
  • University of Turku (FI)
  • University of Helsinki (FI)
  • Tampere University Hospital (FI)
  • University of Oulu (FI)
  • Tampere University (FI)
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-11
Volume
372
Issue
9651
Pages
1746-1755
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(08)61309-4
OpenAlex
W2157440365
Cited by
382
References
32
Citations by year
2026: 3 · 2025: 10 · 2024: 19 · 2023: 15 · 2022: 16 · 2021: 21 · 2020: 19 · 2019: 16 · 2018: 19 · 2017: 8 · 2016: 21 · 2015: 33 · 2014: 19 · 2013: 36 · 2012: 30
FWCI
18.28
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
type 1 diabetes prevention, nasal insulin, diabetes-associated autoantibodies, high genetic risk, children, siblings, diabetes onset, diabetes screening, cord blood screening, early trial termination, diabetic mouse model, insulin resistance index
MeSH terms
Administration, Intranasal, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Finland, Genetic Testing, Genotype, HLA-DQ Antigens, Humans, Hypoglycemic Agents, Infant, Infant, Newborn, Insulin, Male, Risk Factors, HLA-DQ beta-Chains

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review